Sign In
Buy OBSV
$0.102
+0 (+0%)
At Close: Jun 21, 2023
Catabasis (CATB) Partners with UK-Based Charity for DMD Study
09:09pm, Thursday, 09'th Jan 2020
Catabasis (CATB) teams up with Duchenne UK to fund a phase II study of its pipeline candidate edasalonexent, now being developed to treat patients with non-ambulatory Duchenne muscular dystrophy.
ObsEva SA to Participate in in JP Morgan Healthcare Conference January 13-16, 2020
06:00am, Tuesday, 07'th Jan 2020
Geneva, Switzerland and Boston, MA – January 7, 2020 - ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to.
ObsEva SA (OBSV) Is Burning These Hedge Funds
11:10am, Monday, 16'th Dec 2019
We are still in an overall bull market and many stocks that smart money investors were piling into surged through the end of November. Among them, Facebook and Microsoft ranked among the top 3 picks a
3 Biotech Stocks That Offer the Highest Upside on Wall Street
09:11pm, Thursday, 12'th Dec 2019
For the uninitiated, biotech stocks can seem a tad intimidating. The untrained eye is confronted with masses of obscure data, clinical trial information and industry specific medical jargon. Once crac
ObsEva's Menstrual Bleeding Drug Produces 'Best-In-Class' Response In Late-Stage Study
04:53pm, Monday, 09'th Dec 2019
Swiss biopharma Obseva SA (NASDAQ: OBSV ), which is developing orally administered, clinical-stage compounds to treat women's reproductive health conditions, announced a positive late-stage clinical r
ObsEva Announces Positive Results from Uterine Fibroids Phase 3 Study (PRIMROSE 2) of Linzagolix
06:00am, Monday, 09'th Dec 2019
ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health, today reported positive Phase 3 trial results
ObsEva SA to Hold Conference Call to Discuss PRIMROSE 2 Trial Results on December 9, 2019
09:30pm, Friday, 06'th Dec 2019
Geneva, Switzerland and Boston, MA –December 6, 2019 - ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to.
ObsEva Sees Hammer Chart Pattern: Time to Buy?
11:49am, Tuesday, 03'rd Dec 2019
ObsEva has been struggling lately, but the selling pressure may be coming to an end soon.
Edited Transcript of OBSV.O earnings conference call or presentation 7-Nov-19 1:00pm GMT
07:44pm, Monday, 18'th Nov 2019
Q3 2019 Obseva SA Earnings Call
